FDA Approved: TRADJENTA — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approves a supplemental application for TRADJENTA (linagliptin) submitted by Boehringer Ingelheim, resulting in changes to the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Tradjenta (Linagliptin)

Snippet

SUPPL AP for TRADJENTA (LINAGLIPTIN)